The efficacy of DEFINITY administration during echocardiography was assessed in a prospective independent blinded evaluation of non-contrast and DEFINITY contrast images for left ventricular ...

References: Lantheus announces the FDA approval of Definity ® (perflutren lipid microsphere) for pediatric patients. News release. Lantheus Holdings, Inc. March 4, 2024. https://investor.lantheus ...

Definity is in Phase 3 for pediatric echocardiography. Revenue for Definity can expand if this indication achieves an approval. About 1.3% of U.S. children have a heart condition.

Lantheus Holdings, Inc. LNTH recently announced that the FDA has approved the supplemental new drug application for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound-enhancing agent for use ...